Research programme: ovarian cancer therapeutics and diagnostics - Abeome/RayBiotech

Drug Profile

Research programme: ovarian cancer therapeutics and diagnostics - Abeome/RayBiotech

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Abeome Corporation; RayBiotech
  • Developer Abeome Corporation
  • Class Antibodies; Antibody diagnostics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Ovarian cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Ovarian-cancer(Diagnosis) in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Ovarian-cancer in USA
  • 02 Nov 2012 Early research in Ovarian cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top